ABSTRACT:Gastrointestinal dysfunction is common in Parkinson's disease. Fiber therapy could be used to reduce the symptoms of gastrointestinal motility disorders. In a previous study, we showed that slowed gastrointestinal motility modified levodopa pharmacokinetics: area under the plasma concentration-time curve (AUC) and maximum plasma concentration (C max ) decreased and the elimination was delayed. In this study, we evaluated whether or not the hydrosoluble fiber Plantago ovata husk is useful in improving levodopa pharmacokinetics in rabbits with autonomic gastrointestinal disorders induced by the administration of the anticholinergic biperiden. Levodopa ؉ carbidopa (20:5 mg/kg), biperiden (100 g/ kg), and P. ovata husk (at two different doses: 100 and 400 mg/kg) were administered orally to rabbits for two periods of time (7 or 14 days). In all groups of animals, the AUC values were approximately 50% higher on the final day of treatment than on day 1. C max was also higher, with the greater increase at the 400 mg/kg dose of fiber, which resulted in a boost of approximately 35%. On day 1 of treatment and with both doses of fiber, AUC values were very similar to those obtained in previous work in rabbits with normal gastrointestinal motility, but the C max was lower. However, after 7 or 14 days, the AUC values were higher, but C max remained lower. The greatest differences were observed in plasma concentration before drug administration (C min ), for which the highest increase was obtained with the dose of 400 mg/kg fiber on day 14 of treatment (349.8%). P. ovata husk could be beneficial in patients with Parkinson's disease because it regulates stool transit in the intestine and because it improves levodopa pharmacokinetics when gastrointestinal peristalsis is slowed. These changes could lead to a possible delay in the onset of dyskinesias and to changes in prognosis.There is growing recognition that one of the most frequent autonomic disorders in patients with Parkinson's disease is gastrointestinal dysfunction (Singer et al., 1992). In a detailed survey, Edwards et al. (1992) compared the frequency of gastrointestinal symptoms in patients with this disease and identified the most common symptoms as abnormal salivation, dysphagia, nausea, constipation, and defecatory dysfunction.Constipation has been reported in more than 50% of patients with Parkinson's disease who attended a movement disorders clinic (Edwards et al., 1991). In elderly individuals, constipation may correlate with decreased physical activity, a low fluid intake, a diet poor in fiber, a sedentary life style, and the illness itself (Müller-Lissner et al., 2005).Levodopa is the most effective antiparkinsonian drug available and is usually administered with an inhibitor of dopa decarboxylase such as carbidopa or benserazide. It is administered orally, and, therefore, its rate of absorption from the gastrointestinal tract has an important influence on its clinical effect. Stomach emptying rate and gastrointestinal motility are important factors af...